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Research Article
Interleukin-18 produced by bone marrow-
derived stromal cells supports T-cell acute
leukaemia progression
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Abstract
Development of novel therapies is critical for T-cell acute leukae-
mia (T-ALL). Here, we investigated the effect of inhibiting the
MAPK/MEK/ERK pathway on T-ALL cell growth. Unexpectedly, MEK
inhibitors (MEKi) enhanced growth of 70% of human T-ALL cell
samples cultured on stromal cells independently of NOTCH activa-
tion and maintained their ability to propagate in vivo. Similar
results were obtained when T-ALL cells were cultured with ERK1/
2-knockdown stromal cells or with conditioned medium from
MEKi-treated stromal cells. Microarray analysis identified interleu-
kin 18 (IL-18) as transcriptionally up-regulated in MEKi-treated
MS5 cells. Recombinant IL-18 promoted T-ALL growth in vitro,
whereas the loss of function of IL-18 receptor in T-ALL blast cells
decreased blast proliferation in vitro and in NSG mice. The NFKB
pathway that is downstream to IL-18R was activated by IL-18 in
blast cells. IL-18 circulating levels were increased in T-ALL-xeno-
grafted mice and also in T-ALL patients in comparison with
controls. This study uncovers a novel role of the pro-inflammatory
cytokine IL-18 and outlines the microenvironment involvement in
human T-ALL development.
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Introduction
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive
haematologic malignancy accounting for about 15% of paediatric
and 25% of adult ALL (Pui et al, 2004). T-ALL originates from a
block of differentiation and uncontrolled proliferation of developing
T cells and is lethal without therapy. Current chemotherapies
provide an overall survival (OS) higher than 75% in children (Pui
et al, 2008) and of about 50% in adults at 5 years (Marks et al,
2009). Both paediatric and adult relapses have a very poor outcome.
Therefore, the identification of molecular targets and the develop-
ment of specific therapies are major goals that require a better
understanding of T-ALL molecular mechanisms.
In T-ALL, many oncogenic pathways are often activated due to
chromosomal abnormalities (Ferrando et al, 2002), and the disease
can thus be classified into distinct molecular groups with specific
gene expression signatures (Van Vlierberghe & Ferrando, 2012).
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Transcription factors, among which TAL1 (T-cell acute lymphocytic
leukaemia 1; also known as SCL) and HOX11L2 (homeobox-11/L2;
also known as TLX3), are frequently deregulated (Graux et al, 2006).
Signalling pathways also are often perturbed. For instance, PTENmuta-
tions are common in leukaemic blasts and may lead to the activation of
the PI3K/AKT pathway (Palomero et al, 2007; Silva et al, 2008).
The mitogen-activated protein kinase (MAPK) signalling cascade,
one of the pathways that mediate proliferation and differentiation of
hematopoietic cells (Lee & McCubrey, 2002), is frequently deregulat-
ed in adult T-ALL. Among the MAPK pathways, the extracellular
signal-regulated kinases 1 and 2 (ERK1/2), two serine/threonine
protein kinases, the activation of which depends on the upstream
MEK1/2 tyrosine/threonine kinases, are constitutively phosphory-
lated in approximately 38% of patients with T-ALL (Gregorj et al,
2007). Moreover, functional activation of some oncogenic proteins,
such as TAL1/SCL, requires phosphorylation by MEK/ERK kinases
(Cheng et al, 1993; Wadman et al, 1994; Talora et al, 2006). MAPK
inhibitors are thus interesting molecules for T-ALL treatment.
Besides the well-accepted implication of intracellular oncogenic
pathways in T-ALL development, there is increasing evidence that
extracellular signals provided by the microenvironment also partici-
pate in T-ALL onset/progression (Nwabo Kamdje & Krampera, 2011).
Signals initiated by growth factors, such as interleukin 7 (IL-7; Bara-
ta et al, 2001) or insulin growth factor 1 (IGF-1; Medyouf et al, 2011),
or by receptor–ligand interactions, such as NOTCH-Delta-like1/4
(DL1/4; Weng et al, 2003; Armstrong et al, 2009), are crucial for
T-ALL development. The identification of mutations in the genes
encoding components of these signalling pathways further confirms
their importance in T-ALL (Weng et al, 2004; Shochat et al, 2011;
Zenatti et al, 2011). Biological phenomena, such as inflammation, can
also participate in cancer progression, particularly in the case of
haematological malignancies, such as chronic myelomonocytic
leukaemia and lymphomas (Alexandrakis et al, 2004; Liu et al, 2011;
Reynaud et al, 2011). However, it is not known whether an inflamma-
tory environment plays a role in T-ALL development/progression.
In the present work, we investigated whether inhibition of the
MEK/ERK pathway could hinder T-ALL progression. Unexpectedly,
MEK inhibition (MEKi) increased T-ALL cell proliferation. We then
demonstrate that this effect is due to MEKi-mediated increased secre-
tion of the pro-inflammatory cytokine IL-18 by stromal cells. More-
over, patients with T-ALL and immunodeficient mice xenografted
with human T-ALL cells have higher circulating levels of IL-18 than
controls. Although still preliminary, comparison of disease-free
survival in T-ALL patients stratified according to the European
Group of Immunological Classification of Leukaemia (EGIL) relative
to their high/low IL-18 plasmatic level suggests that IL-18 levels may
be of prognosis value in T-ALL. This work demonstrates the impor-
tance of the pro-inflammatory IL-18 cytokine and the major role of
the microenvironment in human T-ALL development/progression.
Results
MEK inhibition promotes human T-ALL cell growth in vitro and
in vivo
To test the effect of MEK inhibition in T-ALL, human T-ALL cell
samples were co-cultured with MS5 or MS5-DL1 stromal cells
directly after isolation from patients or after injection in immuno-
deficient mice (see Supplementary Table S2 for a description of
the 26 T-ALL samples used in this study) in the presence of a
MEKi (U0126, PD98059 or PD184352). T-ALL cells were then
counted by FACS analysis (CD45+CD7+ cells) or trypan blue
staining at different time points. Overall 20/26 (77%) T-ALL cell
samples could be cultured in vitro and 69% (11/16) of them
proliferated better when grown on MS5-DL1 than on MS5 cells
(Table 1). Surprisingly, cell growth was increased in 14/20 (70%)
of MEKi-treated T-ALL samples compared to untreated co-cultures
(Table 1 and Fig 1A). Similar results were obtained with the three
MEKi PD184352, PD98059 and U0126 (Supplementary Fig S1 and
not shown) and with two other cell feeders (mouse stromal OP9
cells and human mesenchymal stem cells; Supplementary Fig S2).
As MEKi effect on proliferation was milder in T-ALL cells
Table 1. Growth response of T-cell acute lymphoblastic leukaemia
(T-ALL) cells to MEK inhibition
T-ALL samples
Co-culture with
MS5 cells MS5-DL1 cells
Diluent MEKi Diluent MEKi
M18 0 +++ + ++
M18 x ++ ++++ +++ ++++
M22 0 ++ 0 ++
M30 + ++ ++ +++
M34 0 + +++ +++
M40 0 + + ++
M69 x ++ +++ +++ +++
M78 x ++ +++ +++ +++
M86 0 + 0 +
M97 + ++ +++ ++++
M105 +++++ +++++ +++++ +++++
M105 x ++++ ++++ +++ nd
M106 x +++ ++++ ++++ ++++
M108 ++++ +++++ nd nd
M109 0 0 + ++
M110 0 + nd nd
M112 x + + nd nd
M114 +++ ++ +++ nd
M118 0 + +++ nd
M120 + ++ nd nd
M121 0 0 + +
M129 x +++ +++ +++ nd
Human T-ALL cells isolated from newly diagnosed patients or from
xenografted mice (x) were seeded (2 × 105/well in 24-well plates) on MS5 or
MS5-DL1 stromal cells and cultured in the presence of MEKi (1 lM
PD184352) or diluent alone (DMSO, negative control) for 28 days. CD45+CD7+
leukaemic cells were counted at day 28 and (+), (++), (+++), (++++), (+++++)
indicate, respectively, a < 10-fold, between 10- and 50-fold, 50- and 250-fold,
250- and 1,000-fold and higher than 1,000-fold number increase compared
to the original number of seeded cells. 0, no cells were recovered after
culture; nd, not done.
EMBO Molecular Medicine Vol 6 | No 6 | 2014 ª 2014 The Authors
EMBO Molecular Medicine IL-18 participates in human T-ALL Benjamin Uzan et al
822
Published online: April 28, 2014 
cultured on MS5-DL1 than on MS5 cells (Fig 1A and Table 1), we
asked whether NOTCH was implicated in MEKi effect. MEKi did
not significantly modify the expression of the NOTCH target genes
DELTEX, HES1 and PTalpha during culture (Fig 1B and not
shown), indicating that NOTCH is not involved in MEKi effect. In
addition, MEKi-mediated increase in T-ALL cell proliferation did
not correlate with specific NOTCH1 mutations or oncogene activa-
tion (Supplementary Table S2).
Then, MEKi-treated or untreated T-ALL cells (n = 6 different
samples) were injected in immunodeficient NSG mice and leukaemia
development was monitored after 6–8 weeks. Four of the six MEKi-
treated T-ALL samples showed a more aggressive behaviour than
A
B
C
Figure 1. MEK inhibition stimulates the proliferation of T-ALL cells co-cultured with MS5 stromal cells and maintains T-LIC activity.
A T-ALL cells were cultured on MS5 (left panel) or MS5-DL1 (right panel) stromal cells in the presence (MEKi) or not (DMSO alone) of 1 lM PD184352 (MEK inhibitor) for
28 days. Cells were counted by harvesting individual wells from 24-well/plates each week and using trypan blue or FACS. Shown are the cumulative data
(mean  s.d. of triplicates) for the M69 T-ALL sample as representative of the 14 MEKi-responsive T-ALL samples.
B HES1 and DELTEX expression levels in four individual T-ALL samples after 28 days of culture with MS5 or MS5-DL1 cells in the presence or absence of PD98059 (MEKi).
C Engraftment level in bone marrow of T-ALL cells that were cultured with or without MEKi (PD98059: M18, M22, M40; PD184352: M18, M108; U0126: M18, M30) for
1–2 weeks before injection. Left panel shows a representative experiment in which M18x T-ALL cells were injected in NSG mice directly or after 2 weeks of co-culture
with MS5 cells in the presence or not of PD98059. The right panel provides a summary of the engraftment level of all tested T-ALL samples. Transplantations of M18,
M22 and M30 T-ALL treated with PD98059 and U0126 were done in NS mice (Mann–Whitney non-parametric test).
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untreated cells. Overall, significant bone marrow invasion by leukae-
mic blasts (≥ 25% CD45+CD7+ cells) was observed in 70% (28/40)
of mice transplanted with MEKi-treated T-ALL cells compared to
27% (12/44) of animals injected with untreated cells (Fig 1C).
Treatment of stromal cells with MEK inhibitors increases T-ALL
cell growth and enhances IL-18 production
As ERK1/2 phosphorylation was decreased in T-ALL blasts but also
in MS5 cells following incubation with the MEKi PD184352
(Fig 2A), we investigated whether MEKi effect on T-ALL
proliferation was mediated through MS5 cells. To test this
hypothesis, conditioned medium (CM), which was harvested every
other day from MS5 cultures grown in the presence of MEKi, was
added to untreated co-cultures of T-ALL and MS5 cells. Three
independent experiments showed that the addition of CM from
MEKi-treated MS5 cells was sufficient to increase T-ALL cell prolifer-
ation (Fig 2B and data not shown). Similarly, co-culture of T-ALL
samples with MS5 cells in which ERK1 and/or ERK2 were silenced
(shERK1/2 MS5 cells) resulted in a significant increase in blast cell
proliferation compared to control co-cultures (shCTL MS5; Fig 2C
and Supplementary Fig S3). This effect was particularly strong upon
ERK2 silencing. However, it should be noted that shERK1/2 MS5
cells were less viable (not shown), thus explaining their relative
lower support of T-ALL growth compared to shERK2 MS5.
Altogether, these results show that inhibition of the MEK/ERK
MAPK pathway induces the secretion by MS5 feeder cells of factors
that promote T-ALL proliferation.
To identify these factors, we performed gene expression profil-
ing of MS5 cells treated or not with MEKi for 7 days (three inde-
pendent experiments) and identified 110 genes, the expression of
which was modified upon incubation with MEKi (Supplementary
Fig S4 and Fig 2D). Among the up-regulated genes that encode
secreted factors, we selected the pro-inflammatory cytokine IL-18
as it participates in tumour growth and metastasis formation (Kim
et al, 2006, 2007; Amin et al, 2007). In accordance with the
microarray results, a mean 5.8-fold increase (range: 2.65–10.7) of
IL-18 gene expression was observed in MS5 cells upon MEKi
treatment (Fig 2E). Similarly, IL-18 protein concentration was 2.3-
and 2.1-fold higher in CM from PD184352-treated MS5 and from
shERK1/2 MS5 cells, respectively, than in CM from control MS5
cells (Fig 2F).
Stromal cell-secreted IL-18 contributes to human T-ALL growth
in vitro
To determine whether MS5-secreted IL-18 could affect T-ALL cell
proliferation, the expression of the a and b chains of the IL-18
heterodimer receptor (IL-18Ra and IL-18Rb) was quantified in
T-ALL samples and compared with that of normal umbilical cord
blood (UCB) CD7+ T cells (Fig 3A and not shown). The expression
differences probably reflect differences in maturation stages of the
two cell types as IL-18 promotes mature T-helper cell generation
(Nakanishi et al, 2001).
Then, T-ALL/MS5 co-cultures were grown in the presence or not
(control) of recombinant human IL-18 for 4 weeks. Cell proliferation
was increased in six of 10 tested T-ALL samples, compared to
controls (Fig 3B and C and data not shown). Moreover, IFN-c
expression, a downstream target of the IL-18 pathway (Okamura
et al, 1995), was significantly higher in T-ALL cells cultured in the
presence of IL-18 than in controls, indicating that the IL-18 pathway
is activated in T-ALL cells in response to exogenous IL-18 (Fig 3B
and data not shown).
The role of IL-18 in T-ALL cell proliferation was further confirmed
by the finding that addition of an anti-mouse IL-18 neutralizing
antibody (mIL-18Ab) decreased MEKi-induced T-ALL cell
proliferation in T-ALL/MS5 co-cultures (Fig 3C and Supplementary
Fig S5). Similar results were obtained in the five tested
MEKi-responding T-ALL samples. Moreover, mIL-18Ab could reduce
T-ALL cell proliferation in comparison with control cells even in the
absence of MEKi (Fig 3C and Supplementary Fig S5). This effect was
variable, but was particularly strong in the M105 T-ALL sample
(Supplementary Fig S5B), which shows high T-ALL initiating cell
(T-LIC) activity (Gerby et al, 2011). In agreement with IL-18
inhibition, IFN-c levels were lower in blast cells treated with
mIL-18Ab compared to controls (Supplementary Fig S5C). Finally,
the role of stromal cell-derived IL-18 in T-ALL cell proliferation was
also explored in co-cultures of T-ALL and MS5 cells in which IL-18
was silenced (shIL-18). A 75% decrease in IL-18 expression in MS5
cells significantly reduced T-ALL cell proliferation on its own and
also strongly reduced MEKi proliferative effect in comparison with
co-cultures with shCTL MS5 cells (Fig 3D). Similar results were
obtained also when intracellular Notch1 (ICN1)-induced T-ALL
mouse cells were co-cultured with shCTL or shIL-18 MS5 cells
(Supplementary Fig S6).
Figure 2. MEKi induces IL-18 production by MS5 stromal cells.
A Western blot analysis of protein lysates from M97 T-cell acute lymphoblastic leukaemia (T-ALL) cells co-cultured with MS5 or MS5-DL1 (left panel) and from MS5 or
MS5-DL1 cells (right panel) incubated (+) or not () with the MEKi PD184352 for 1 h before harvesting.
B Assessment of M18 T-ALL cell proliferation when cultured in the presence of conditioned medium (CM) from control (DMSO) (CM CTL) or MEKi-treated (1 lM
PD184352, CM MEKi) MS5 cells. Data are representative of three experiments performed in triplicate. Inset shows the details of day 21 (mean  s.d.; Mann–Whitney
non-parametric test).
C Proliferation of M69 T-ALL cells co-cultured with shERK1- and/or shERK2-transduced MS5 cells (inset shows the reduction of ERK1/2 protein expression following
transduction with the different short hairpin RNAs). Data are representative of three experiments performed in triplicate (mean  s.d.; Mann–Whitney non-
parametric test). tERK1/2, total ERK1/2 proteins.
D Microarray analysis (Affymetrix arrays) of MS5 cells cultured in the presence of 1 lM PD184352 (MEKi) or diluent for 7 days. Heatmap shows the transcripts, the
expression of which was most significantly different in the two conditions (arrow indicates IL-18).
E IL-18 mRNA expression in MS5 cells grown in the presence of 1 lM PD184352 or not (diluent) for 1 week (mean  s.d. of five independent experiments).
F IL-18 protein expression in the supernatants of MS5 cells treated with 1 lM PD184352 or diluent for 1 week and in the supernatants of MS5 cells 1 week after
transduction with shERK1+2 or shCTL (mean  s.d. of triplicates; Mann–Whitney non-parametric test).
Source data are available for this figure.
▸
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As abnormal constitutive NF-jB activation plays an important
role in controlling T-ALL cell proliferation (Kordes et al, 2000), we
hypothesized that IL-18 may activate NF-jB. Indeed, recombinant
IL-18 led to a significant increase in NF-jB DNA binding activity in
T-ALL cells (Supplementary Fig S5D and E). Moreover, both basal
and IL-18-induced NF-jB activation were higher in M105 T-ALL
cells co-cultured with MS5 cells than without. Importantly, NF-jB
DNA binding activity was strongly reduced when T-ALL cells were
cultured with shIL-18 MS5 cells in comparison with shCTL MS5 cells
(Supplementary Fig S5E). NF-jB activation in T-ALL was also
observed when blast cells were cultured with CM from MEKi-treated
MS5 cells, supporting a link between MEKi, IL-18 and NF-jB activa-
tion (Supplementary Fig S5F).
IL-18Ra silencing in T-ALL cells further supported the involve-
ment of stromal IL-18 in leukaemic cell proliferation (Supplemen-
tary Fig S7). Indeed, proliferation of shIL-18Ra T-ALL cells was
reduced compared to shCTL T-ALL cells (Fig 3E and F). Less than
2% of T-ALL cells were GFP negative (thus not infected) after
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transduction with shIL-18Ra or shCTL (Fig 3E, left panels) and this
level progressively raised to 48% in T-ALL cells transduced with
shIL-18Ra, while it remained stable (1.2%) in T-ALL cells trans-
duced with shCTL at day 38 of co-culture with MS5 cells (Fig 3E,
right panels and Fig 3F). At the end of the experiment, it was
confirmed that IL-18Ra expression was strongly decreased only in
shIL-18R/GFP+ T-ALL cells, but not in shCTL/GFP+ and shIL-18Ra/
GFP T-ALL cells (Fig 3G). Altogether, these data indicate that
stromal IL-18 contributes to human T-ALL cell proliferation, possi-
bly through activation of the NF-jB pathway.
Interfering with the IL-18 pathway in human T-ALL cells delays
leukaemia development in vivo
We next investigated whether interfering with the IL-18 pathway
affects leukaemia development in vivo. First, NSG mice were
injected with three T-ALL cell samples pre-treated or not (control)
with mIL-18Ab for 2 weeks. Bone marrow monitoring at week 6
post-xenograft indicated that the leukaemic load was significantly
lower in two of the three pre-treated T-ALL samples in comparison
with controls (Fig 4A). However, animals’ survival was not
improved (Fig 4B). This indicates that transient pre-treatment with
mIL-18Ab in vitro does not durably interfere with T-ALL cell expan-
sion in vivo. Then, NSG mice were transplanted with shIL-18Ra
T-ALL or shCTL T-ALL (control) cells. In agreement with our
in vitro results (Fig 3E and F), CD7+GFP leukaemic blasts showed
a growth advantage over CD7+GFP+ cells in several animals
injected with shIL-18Ra T-ALL cells compared to control mice
(Fig 4C). Moreover, the spleens from mice transplanted with
shIL-18Ra T-ALL cells were significantly smaller than those of
control animals (Fig 4D). Survival of mice injected with shIL-18Ra
T-ALL cells was significantly improved compared to controls
(Fig 4E). Altogether, these data indicate that IL-18 contributes to
T-ALL progression in xenograft models.
IL-18 levels are increased in T-ALL-xenografted mice and in
patients with T-ALL
Finally, measurement of IL-18 levels in serum samples of xenograft-
ed mice indicated that IL-18 concentration was higher (threefold) in
NSG mice injected with human T-ALL cells (n = 20; six different
T-ALL samples) compared to age-matched non-transplanted mice
(n = 19; Fig 5A), suggesting that T-ALL development drives IL-18
production in mice. Interestingly when looking into mouse IL-18
production either in tumour-free (Fig 5B) or in tumour-bearing (not
shown) NSG mice, we found that haematopoietic CD45+ and
non-haematopoietic CD45 cells could produce IL-18, suggesting
that BM cells constitute a reservoir of IL-18 (Arend et al, 2008).
Similarly, IL-18 plasma levels were significantly increased also in
patients with T-ALL (mean  s.d.: 337  34 pg/ml; n = 92)
compared to healthy paediatric controls (mean  s.d.: 71  12 pg/
ml; n = 29; Fig 5C). Moreover, IFN-c plasma levels, an indication of
IL-18 pathway activation (Okamura et al, 1995), were also
significantly increased in patients with T-ALL (n = 25) compared to
controls (n = 15; Fig 5D), and probably as a consequence also there
was an increase in IL-18-binding protein (IL-18BP, Supplementary
Fig S8; Dinarello et al, 2013). Interestingly, free IL-18 levels,
calculated according to (Novick et al, 2001), showed an excel-
lent correlation with total IL-18 concentrations (Supplementary
Fig S8).
To determine the clinical impact of circulating IL-18 levels, the
clinical features of 81 patients with T-ALL were analysed relative to
their IL-18 plasma levels. Comparative analysis of patients with high
(over the median value, n = 40 patients) and low (under the median
value, n = 41 patients) IL-18 plasma levels found no correlation
with age, sex, CNS involvement, white blood cell count, EGIL classi-
fication, cytogenetic abnormalities, and response to prephase treat-
ment (Table 2). Mediastinal enlargement/effusions were more
frequent in the low IL-18 than in the high IL-18 group (Table 2).
Likewise, the low IL-18 group of patients included 5/6 T-lympho-
blastic lymphomas. Disease-free survival was not impacted by the
IL-18 secretion level (not shown). As it was reported that the immu-
nophenotype could influence the outcome of patients with T-ALL
(Niehues et al, 1999), we tested the prognostic impact of the EGIL
TIII and not-TIII (i.e. T I/II/IV) phenotypes. While no significant
difference in the whole population was observed (data not shown),
when IL-18 levels are combined with EGIL stratification in a
Cox-regression model, EGIL TIII IL-18 low patients tend to show a
better prognosis than EGIL not-TIII low IL-18 patients [HR = 3.9,
95% IC (1.02–18), P = 0.046] and in a much lesser extent than high
IL-18-EGIL TIII [HR = 2.5, 95% IC (0.55–11), P = 0.24] and high
IL-18-EGIL not-TIII [HR = 2.5, 95% IC (0.63–10), P = 0.19;
Supplementary Fig S9]. These data remain preliminary and further
analyses remain to be performed before to conclude on a prognosis
Figure 3. IL-18 promotes T-cell acute lymphoblastic leukaemia (T-ALL) growth in vitro.
A Cell surface expression of IL-18Ra (left panel) and IL-18Rb (right panel) in M106 and M114 T-ALL cells. Histograms show the mean fluorescence intensity (MFI) of
IL-18Ra and IL-18Rb staining in, respectively, 7 and 11 T-ALL samples. Control: T-ALL or UCB CD7+ T cells stained with isotype control antibodies.
B IL-18 stimulates T-ALL cell proliferation. 2.105 M18 T-ALL cells were cultured on MS5 and in the presence or not (CTL) of recombinant human IL-18 for 28 days.
Cells were harvested every week, counted and re-plated. Data are representative of five experiments performed in triplicate. Inset shows the quantification of
IFN-c mRNA expression levels in IL-18-treated and control T-ALL samples at day 28 of culture.
C M30 T-ALL proliferative response when cultured in the presence of MEKi (1 lM PD184352), recombinant IL-18 or an antibody against mouse IL-18 (mIL-18Ab) for
28 days. Data are the mean  s.d. of triplicates. Results are representative of 2–5 T-ALL samples/condition. n.s., not significant.
D Proliferative response of M105 T-ALL cells cultured on MS5 cells in which IL-18 was silenced (shIL-18) or not (shCTL) and in the presence or not of MEKi (1 lM
PD184352) for 21 days. Inset shows the quantification of IL-18 mRNA in MS5 cells transduced with shIL-18 or shCTL (data are representative of two samples in
three experiments performed in triplicate).
E–G In vitro growth of M105 T-ALL cells in which IL-18Ra was silenced or not with shIL-18Ra/GFP or shCTL/GFP lentiviral vectors. Cells were transduced, sorted for
GFP expression (E, day 0) and co-cultured with MS5 cells for 38 days. Quantification of GFP+ and GFP/low cells at different time points (F). Black line, shCTL
cells; grey line, shIL-18Ra cells. At day 38, T-ALL cells were sorted according to their GFP expression and IL-18Ra expression was quantified (G). Two independent
experiments were performed.
Data information: Mann–Whitney non-parametric test was used for statistics.
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value of circulating IL-18 levels for T-ALL patients classified accord-
ing to their EGIL phenotype.
Discussion
We previously showed that T-ALL cells require stromal support for
in vitro growth and that the NOTCH pathway is of particular impor-
tance for their maintenance (Armstrong et al, 2009), a finding that
is supported by a recent study (Yost et al, 2013). Here, we used the
T-ALL/MS5 stromal cell co-culture system to explore the role of the
MEK/ERK pathway in T-ALL cell expansion. Unexpectedly, treat-
ment with MEK inhibitors improved proliferation of about 70% of
human T-ALL cell samples co-cultured with MS5 cells. This effect
was not NOTCH dependent because MS5 cells do not express robust
levels of NOTCH ligand DL1 and NOTCH target genes were not acti-
vated upon incubation with MEK inhibitors. However, the finding
that proliferation of T-ALL cells co-cultured with MS5-DL1 cells was
only moderately modified following MEK inhibition suggests the
existence of different T-ALL supporting niches. We then demon-
strate that MEK inhibitors stimulate T-ALL cell proliferation through
the induction of IL-18 secretion by MS5 cells.
These findings strongly support the hypothesis that cross-talk
between stromal/microenvironmental cells and leukaemic blasts is
crucial during T-ALL development (Nwabo Kamdje & Krampera,
2011). An emerging notion is that aberrant activation of signal trans-
duction pathways in leukaemia cells can be induced by interactions
with stromal cells of the bone marrow or thymus microenvironment
(Konopleva & Andreeff, 2007; Lane et al, 2009). An altered microen-
vironment may even rupture the homeostasis and favour the early
B
Log-rank (Mantel-Cox) 
p=0.2727
A
CTL mIL18Ab
M129
CTL mIL18Ab CTL mIL18Ab
M108
ns
M18
p=5x10-4 p=0.031
C
shCTL
G
FP
CD7
Mouse 1 Mouse 2
Mouse 3 Mouse 4
shIL18Rα Log-rank (Mantel-Cox) 
p=0.0012
E
p=0.0095
D
Figure 4. Interfering with IL-18 activity delays leukaemia progression in xenografted mice.
A Proportion of human leukaemic blasts (CD45+CD7+ cells using anti-human CD45 and CD7 antibodies) in the bone marrow of NSG mice at week 6 after intravenous
injection of 0.5–5 × 103 M129 (left panel), M18 (middle panel) or M108 (right panel) T-cell acute lymphoblastic leukaemia (T-ALL) cells that were pre-treated in vitro
with mIL-18Ab or with isotype control Ab (CTL) for 2 weeks.
B Survival curves of NSG mice transplanted with M129 T-ALL cells and shown in (A).
C GFP expression in CD45+CD7+ leukaemic blasts recovered from NSG mice transplanted with M105 T-ALL cells that were transduced with shIL-18Ra/GFP (n = 10
mice) or shCTL/GFP vectors (n = 9 mice). Shown are results of four representative animals.
D After euthanasia, spleens were recovered and weighed (mean  s.d. of four mice transplanted with shCTL M105 T-ALL and six animals injected with shIL-18Ra M105
T-ALL).
E Survival curves of mice transplanted with 5 × 103 shCTL or shIL-18Ra M105 T-ALL GFP-positive cells.
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steps of transformation (Raaijmakers et al, 2010). Moreover, stro-
mal cells can provide not only an adequate metabolic environment
for leukaemic cells via activation of survival mechanisms, but also a
protective niche to enhance resistance to chemotherapy (Zhang
et al, 2012). Cytokines and growth factors secreted by stromal cells
are suspected to exert a protective effect not only on the bulk of the
leukaemic cell population, but also on the rare leukaemia initiating
cells (LIC; Konopleva et al, 2009). In particular, it has been estab-
lished that T-ALL cell proliferation and survival is regulated by
several factors, including IL-7 and IGF-1 (Barata et al, 2001, 2004;
Medyouf et al, 2011). These factors are likely to be produced by the
microenvironment, particularly by bone marrow stromal cells (Bara-
ta et al, 2001, 2004; Scupoli et al, 2008). The increased expression
of IL-18 in MEKi-treated MS5 stromal cells together with the detec-
tion of IL-18Ra/b in T-ALL primary cells and the finding that IL-18
incubation stimulates proliferation in more than half of the tested
T-ALL samples strongly suggest that IL-18 also should be included
among the microenvironmental signals supporting leukaemia
development/progression.
IL-18 plays an important pro-inflammatory role (Mariathasan
et al, 2004) and is involved in the induction of inflammatory medi-
ators (Arend et al, 2008). Inflammation is implicated in the
progression of different haematological or non-haematological
malignancies, and several pro-inflammatory factors, such as IL-6
and TNF-a, play a role in cancer development or progression (Liu
et al, 2011; Reynaud et al, 2011). The B-ALL microenvironment is
also described as inflammatory (Espinoza-Hernandez et al, 2001;
Purizaca et al, 2012), further supporting the more general role of
inflammation in acute lymphoblastic leukaemia. Moreover, elevated
levels of IL-18 have been detected in solid tumours (Ye et al, 2007)
similar to the levels we measured in T-ALL patients. Macrophages,
chondrocytes and osteoblasts as well as medullary dendritic cells are
known IL-18 producers (Arend et al, 2008), and here, we show that
stromal/MSC cells also produce IL-18. In addition, IL-18 circulating
levels were higher in NSG mice xenografted with human T-ALL cells
in comparison with controls, arguing that IL-18 is induced in the
environment following leukaemic blast spreading.
The role of IL-18 as a pro- or anti-tumour agent has been
discussed in the literature and seems greatly dependent on the
cancer cell type (Park et al, 2007). Our findings indicate that, in
patients with T-ALL (and also in T-ALL xenograft models), IL-18
production is enhanced and it acts as a tumour cell proliferative
factor. However, we cannot exclude the possibility that IL-18 might
also drive the anti-tumour immune response in vivo, particularly
through enhanced production of IFN-c during the early stages of
T-ALL development. Indeed, in some co-cultures, we observed that
A
B
C D
Figure 5. IL-18 production is increased in xenografted mice and in leukaemic patients.
A Circulating IL-18 expression levels in NSG mice injected with the indicated T-ALL samples (controls are non-transplanted 8- to 12-week-old NSG mice). Serum
samples were collected at the time of euthanasia (6–12 weeks post-transplant) and IL-18 levels were measured by ELISA. Mann and Whitney non-parametric
test was used for statistics.
B Detection of IL-18 expression in BM from a tumour-free NSG mice. Medullary cells were recovered after flushing and crushing bones. Detection of IL-18
expression was measured by flow cytometry after permeabilization and anti-IL-18 labelling of BM cells.
C, D Human IL-18 and IFN-c levels in plasma samples from paediatric patients with T-ALL (IL-18: n = 92 and IFN-c: n = 25) and healthy controls (IL-18: n = 29 and
IFN-c: n = 15). Statistical analyses were carried out using Student’s t-test (C) or Mann–Whitney non-parametric test (D).
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normal T cells, which are present in the samples isolated from
newly diagnosed patients, proliferated in response to IL-18 and
could overtake leukaemic blasts (data not shown), suggesting that
some of the remaining immune cells also are sensitive to IL-18.
Moreover, development of ICN1-driven mouse leukaemia is
favoured in IL-18/ mice in correlation with a reduction in the
number of immunocompetent cells, indicating that the immune
system is important for controlling T-ALL development (unpub-
lished observations and; Schneider et al, 2010). IL-18 is indeed
described as a regulator of the cytotoxic activity of NK and mature T
cells and supports the differentiation and activation of different
T-helper (Th) cell subsets, depending on the surrounding cytokine
profile (Gracie et al, 2003). In combination with other interleukins,
such as IL-12 and IL-15, IL-18 can be used to pre-activate NK cells
with anti-tumour functions (Ni et al, 2012). Thus, targeting IL-18 in
patients with T-ALL needs to be carefully examined because it may
also result in reduction of the immune response as previously
suggested for other tumours (Park et al, 2007).
Our results show that mice xenografted with T-ALL cells in which
IL-18Ra was silenced have reduced splenomegaly and better survival
than animals injected with control T-ALL cells. This result supports
the pro-leukaemia effect of stromal IL-18 in T-ALL, possibly through
enhanced growth in the medullary microenvironment. However, as
the white blood cell count was not particularly higher in high IL-18
patients compared to low IL-18 patients, the medullary niche could
also offer a protective area for IL-18-responding patients and addi-
tional, unknown factors might be implicated in the stroma/leukaemic
blast cross-talk. This is supported by the finding that IL-18 does not
increase proliferation of primary T-ALL cells cultured without stromal
cell support (not shown). In pathologies such as rheumatoid arthritis,
IL-18 has been shown to promote migration, adhesion and activation
of leucocytes through the release of different factors such as
SDF1/CXCL12 and VCAM1/ICAM1 (Komai-Koma et al, 2003; Volin &
Koch, 2011). The implication of IL-18 in these biological processes
during T-ALL development/progression should be further explored.
There is some evidence for a role of the microenvironment in the
outcome of acute leukaemia mainly due to the protective effect of
the bone marrow niche on LICs against chemotherapeutic agents
(Ayala et al, 2009). Although our data on patients’ outcome accord-
ing to the IL-18 secretion level need to be extended to a larger cohort
and also to a supplementary and independent group of patients,
they suggest that the microenvironment plays a role in T-ALL
outcome via secreted factors. Dissecting further the clinical impact
of microenvironmental factors in T-ALL will certainly be of a
particular importance for future therapeutic strategies.
To summarize, here we show that T-ALL cell expansion is
supported by the pro-inflammatory IL-18 cytokine secreted by bone
marrow-derived stromal cells. These results highlight the implica-
tion of the microenvironment in human T-ALL progression and the
relevance of studying the interactions between leukaemic blasts and
feeder cells for identifying novel therapeutic strategies.
Materials and Methods
Patients and cell samples
Primary T-ALL cell samples were collected after obtaining informed
consent by the patients or the patient’s relatives in accordance with
the Declaration of Helsinki and French ethics regulations. Blood
cells were ficolled, immunophenotyped and directly used, or stored
frozen. All patients were treated with an ALL-BFM-based strategy in
the EORTC 58881 and 58951 trials (Clappier et al, 2010). The
INSERM ethical committee (IRB000003888) approved the project
(evaluation number 13-105-1). ICN1-induced mouse T-ALL cells were
obtained as described (Gachet et al, 2013).
The choice of samples used for experiments was motivated by
the availability of enough cells from individual patients and also to
optimization of protocols, such as lentiviral transduction, on some,
but not all, samples.
Plasma samples used for measuring IL-18 and IL-18BP levels
were all from children (T-ALL cohort and controls). These patients
are different from the ones used for functional experiments and
Table 2. Correlative analysis of IL-18 plasma levels and different
clinical parameters in a cohort of 81 patients with T-cell acute
lymphoblastic leukaemia (T-ALL) (n = 77)/T-lymphoblastic lymphoma
(LBL; n = 4)
T-ALL/T-LBL IL-18
plasmatic level (n = 81) Statistical
significance
(c2 or Fisher’s
exact test)
Upper levela
(n = 40)
Low levela
(n = 41)
Age
≤ 10 years (%) 22 (55) 20 (49) NS
> 10 years (%) 18 (45) 21 (51)
M/F ratio 3.0 2.7 NS
Mediastinal
involvementb +
effusionc (%)
3 (7.5) 15 (37) P < 0.01
Tumour spreadingd
(%)
29 (72) 22 (54) NS
CNS involvement (%) 2 (5) 3 (7) NS
WBC (%)
< 100 G/l 21 (53) 28 (68) NS
≥ 100 G/l 19 (47) 13 (32)
European Group of Immunological Classification of Leukaemia (%)
T I/II 13 (32) 11 (27) NS
T III 19 (48) 25 (61)
T IV 6 (15) 3 (7)
Non-classified 2 (5) 2 (5)
Cytogenetic
abnormalities
(n = 35) (n = 36) NS
Yes (%) 26 (74) 23 (64)
No (%) 9 (26) 13 (36)
Response to prephase (%)
Poor 17 (42) 11 (27) NS
Good 23 (58) 30 (73)
aBased on the median secretion level; bchest X-ray assessment; cpleural and/
or pericardial. dSpleen, liver, lymph nodes > 2 cm, kidney, testis, skin (at least
two organs involved). Response to prephase was assessed after 7 days of
steroid treatment (60 mg/m2/day) + intrathecal methotrexate and defined
as: poor ≥ 1 G/l peripheral blasts; good < 1 G/l peripheral blasts.
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represent a retrospective cohort. Plasma samples from a subgroup
of these T-ALL patients (those with the highest IL-18 level) and from
a randomly chosen group of children controls were used for IFN-c
measurements.
MS5 cells
Mouse stromal MS5 and MS5-DL1 (expressing the NOTCH
ligand DL1) cells were described previously (Armstrong et al, 2009).
Culture conditions
T-ALL cells (100–250 × 103/well) were cultured as in (Arm-
strong et al, 2009). MEK pharmacological inhibitors (MEKi:
U0126, PD98059, PD184352; Selleckchem/Euromedex, Souffel-
weyersheim, France) were diluted in DMSO and used at 20, 10
and 1 lM, respectively, or as otherwise indicated. MEKi, recom-
binant human IL-18 (100 ng/ml; Biovision/Clinisciences, Nanter-
re, France) and neutralizing anti-IL-18 antibodies (200 ng/ml;
MBL/CliniSciences) were added in the culture medium 3 times/
week. ICN1-induced mouse T-ALL cells were cultured as in
Gachet et al, (2013). Growth was measured by gating on
CD45+CD7+ blast cells using flow cytometry as in Armstrong
et al (2009).
Flow cytometry
Cells were stained with fluorescein (FITC)-, phycoerythrin (PE)-,
PE-cyanin7 (PC7)- and allophycocyanin (APC)-conjugated mouse
monoclonal antibodies (mAbs) specific for human CD45 (J33), CD7
(8H8.1) (1:50 dilution, Beckman Coulter; Roissy CDG, France and
eBioscience, Paris, France), IL-18Ra and IL-18Rb (FAB840P and
FAB118P, 1:10 dilution; R&D Systems, Lille, France) and analysed
using a FACSCalibur cytometer (BD Biosciences, Le Pont de Claix,
France). For intracellular mIL-18 detection in murine BM, cells were
permeabilized using BD Cytofix/CytopermTM (BD Biosciences)
according to the manufacturer’s protocol. Then, cells were stained
with a purified rabbit anti-IL-18 (H-173) antibody (Santa Cruz
Biotechnology, Dallas, TX, USA), and IL-18 expression was revealed
by FACS using an anti-rabbit Alexa 647 antibody (Molecular Probes,
Eugene, OR, USA). Cell sorting was performed using an Influx cell
sorting cytometer (BD Influx system; BD Bioscience). ICN1-induced
mouse T-ALL cells were monitored with an anti-mouse CD45 mAb
(eBioscience).
Lentiviral vectors and transduction of stromal cell lines and
T-ALL primary cells
IL-18Ra gene silencing in primary T-ALL cells
The IL-18Ra short hairpin RNA (shRNA, 50-GCCTGTTCTTT
CCGAGTCTTA-30), the expression of which is driven by the H1
promoter, was subcloned in the pTRIP/DU3-MND-GFP vector as in
previous studies (Kusy et al, 2010). The control hairpin sequence
(shCTL) targets the human hepatitis B virus. Human T-ALL cells
were transduced with not concentrated G/IL-7SUx envelope
pseudotyped vectors as in Gerby et al, (2010). Transduced
cells were sorted based on the CD45+CD7+GFP+ phenotype before
use.
ERK and IL-18 gene silencing in MS5 cells
The H1-shRNA cassettes against mouse ERK1 and ERK2 (kindly
provided by Dr P. Lenormand, Institute of Signalling Developmental
Biology and Cancer, Nice, France; Lefloch et al, 2008) were subcloned
in the pTRIP/DU3-EF1a lentiviral vector. The same strategy was used
to knock down mouse IL-18 in MS5 cells with a shRNA against
mouse IL-18 (shRNA/mIL-18, 50-CCTCTCTGTGAAGGATAGTAA-30).
Subconfluent MS5 cells were incubated with supernatants containing
the vectors for 3 days, then carefully washed and a sample was
harvested to quantify transduction by measuring GFP expression by
FACS. Silencing efficiency was assessed by QPCR (IL-18) or by
western blotting (ERK1/2). Control shCTL was as for T-ALL cells.
Microarray analysis
RNA was extracted from MS5 cells incubated or not with 1 lM
PD184352 for 7 days (three independent experiments = six samples
in total) and was spotted on whole-genome arrays (mouse Gene1.0
ST; Affymetrix, Bucks, UK). First, we compared all treated and
untreated samples to identify genes differentially expressed and then
we crossed the data from the three independent experiments. Exper-
imental details are provided in Supplementary Fig S4.
Bioinformatics
Quality assessments, normalization and statistics
Raw data were normalized using the Robust Multichip Algorithm
(RMA) in Bioconductor R. Then, all quality controls and statistics
were performed using Partek GS. Hierarchical clustering (Pearson’s
dissimilarity and average linkage) and principal component analysis
were used. To find genes that were differentially expressed in
treated and untreated samples, we applied a classical analysis of
variance for each gene and carried out pairwise Tukey’s post hoc
tests between the groups. We then considered P-values ≤ 0.05%
and a ≥ 1.5-fold change as significant for filtering and selecting
differentially expressed genes.
Functional analysis
Interactions, pathways and functional enrichment analyses were
carried out using IPA (Ingenuity Systems, USA www.ingenu-
ity.com). All microarray analysis data have been submitted to GEO
Omnibus (accession number: GSE43623).
Immunoblot analysis
Total proteins from T-ALL or MS5 cells were extracted with 1× lysis
buffer, separated by 12% SDS–PAGE and transferred onto nitrocellu-
lose membrane (GE Healthcare, Velizy-Villacoublay, France).
Membranes were incubated with antibodies against phospho-p44/42
MAPK (ERK1/2) (Thr202/Tyr204) (4376; Ozyme, Saint Quentin
Yvelines, France), p44/42 MAPK (ERK1/2) (4695; Ozyme) and
b-actin (clone AC-15; Sigma-Aldrich). Proteins were detected with
the ECL PLUS chemiluminescent substrate (GE Healthcare).
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared, and 15 lg of proteins was
analysed for DNA binding activity using the HIV-LTR tandem jB
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oligonucleotide as a probe for NF-kB (Jacque et al, 2005). Samples
were then resolved by electrophoresis using acrylamide/bisacryla-
mide/TBE gels.
IL-18 and IL-18BP plasma levels
IL-18 and IL-18BP plasma levels were measured using ELISA kits
(mouse IL-18 Platinum ELISA, BMS618/2, human IL-18 Platinum
ELISA, BMS267/2CE; eBioscience and human IL-18BP ELISA Kit,
ab100559; Abcam, Paris, France) following the manufacturer’s
instructions. Free IL-18 levels were calculated using IL-18 and
IL-18BP levels as shown in Novick et al, (2001).
Real-time quantitative RT–PCR
RNA was isolated with TRIZOL (Life Technologies, Saint Aubin,
France), reverse-transcribed using random hexamers and the
Superscript RT kit (Invitrogen) according to the manufacturer’s
instructions. The products were used as template for real-time PCR
using the Power SYBR Green PCR Master mix or the TaqMan
Universal PCR MasterMix No AmpErase UNG and the 7300 fast
real-time PCR system (Life Technologies). Raw data were obtained
in terms of Ct values and normalized to the Ct values of the house-
keeping genes GAPDH or b2m. The primer sequences are in
Supplementary Table S1.
Animals
NOD.CB17-Prkdc(scid) (abbreviated NS) and NOD.Cg-Prkdc
(scid)Il2rg(tm1Wjll)/SzJ (abbreviated NSG) mice (The Jackson
Laboratory, Bar Harbor, ME, USA) were housed in pathogen-
free animal facilities at CEA, Fontenay-aux-Roses, France. Mice
were irradiated with 2.5–3 Gy (IBL 637 CisBio International,
France; dose rate: 0.61 Gy/min) and anesthetized with isoflura-
ne before intravenous injection of human leukaemic cells.
Experimental procedures were performed in compliance with
the French Agriculture Ministry and local ethics committee
regulations (Authorization number 12-015). Mice were eutha-
nized when they reached endpoints set to meet accepted animal
care guidelines. Leukaemia progression was monitored using
the anti-human PE-CD45 and PC7-CD7 mAbs (Beckman Coulter
and eBioscience).
Statistical analyses
Statistical significance of comparisons was determined using the
Mann and Whitney non-parametric test. Disease-free survival of
mice was estimated using the Kaplan–Meier method and subgroups
were compared using the log-rank test. Survival of patients was
measured using a Cox-regression model.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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The paper explained
Problem
T-cell acute leukaemia (T-ALL) is an aggressive haematological disor-
der that accounts for 15–25% of acute lymphoblastic leukaemia.
Outcome varies depending on the age of onset, and generally, adults
are much less well cured than young patients. Moreover, relapses
have a very bad prognosis, independently of the patient’s age. There is
thus a great need for complementary therapeutic approaches to
increase patients’ remission. T-ALL development is characterized by
the accumulation of genetic accidents that are considered as targets
for dedicated therapies. Moreover, there is growing evidence that
interactions between leukaemic cells and their microenvironment
promote leukaemia development and progression. This last observa-
tion opens new areas for novel therapeutic developments.
Results
Using the only culture system available for growing ex vivo T-ALL cells
isolated from patients, we uncover the role of the pro-inflammatory
cytokine interleukin 18 (IL-18) in supporting human T-ALL propaga-
tion. We demonstrate that stromal cells that are part of the medullary
microenvironment and are included in the culture system can secrete
IL-18, upon treatment with inhibitors of the MEK/MAP kinase path-
way. Loss of function of IL-18 in stromal cells or knocking down of IL-
18 receptors (IL-18R) in T-ALL blasts seriously interferes with leukae-
mia cell growth in culture. Using mice xenografted with human T-ALL
cells, we show that leukaemia development induces IL-18 production
in these animals. Moreover, in mice xenografted with T-ALL cells in
which IL-18R expression is reduced, leukaemia development is delayed
and animals’ survival extended. Finally, we show that IL-18 plasmatic
levels are also increased in paediatric patients with T-ALL.
Impact
This study outlines the critical interaction between leukaemia cells
and the medullary microenvironment and the positive effect on
tumour growth of microenvironment secreted factors. It highlights a
new mechanism of leukaemia progression and thus may represent an
additional entry for therapies.
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